A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

← catalyst calendar

NCT06551324 · readout in 131 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

600estimated

Sites

224

Countries

Argentina, Australia, Brazil +20

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-10-21

actual

When the study began enrolling

Primary completion

2026-12-28

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-10-29

estimated

The whole study's end, after follow-up

First posted

2024-08-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

Drug: PF-06821497 — also filed as Mevrometostat
Drug: Docetaxel — also filed as Taxotere
Drug: Enzalutamide — also filed as XTANDI

Primary outcome

what the primary-completion date above is the date OF

Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)

measured Randomization up to approximately 2 years.

Publications

PMID 42108644 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed